Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (7761)	1/17/2003 3:58:28 PM
From: tuck	Read Replies (1) of 52153

Rick, It is my understanding that part of the problem with adenoviruses is that the delivered transgene doesn't last. To address that, one strategy has been to link a transposon to the payload. So the vector itself is OK, but now the transposon can go off into unwanted places with attached payload, and you've got potential for insertion mutations again. i-sis.org.uk Apparently, the mutations can a take a good while before manifesting as a problem. Didn't the second patient develop his leukemia three years after treatment? No biotech can afford a trial that long. They would have to follow phase II patients to PIII and beyond or something. Or am I manifesting foot in mouth disease again? Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next